NorthWest Health Prop Real Est Inv Trust (NWH.UN) Stock Price, News & Analysis

Company Overview

Northwest Healthcare Properties Real Estate Investment Trust provides investors with access to a portfolio of high-quality healthcare real estate. The company provides investors exposure to a well-diversified portfolio of healthcare real estate located in the greater areas of cities such as Australasia, Brazil, Germany, and Canada of which Australasia derives a majority of revenue to the company.

Key Stats

• Today's Range: C$4.95 to C$5.05
• 50-Day Range: C$4.69 to C$5.09
• 52-Week Range: C$4.33 to C$5.88
• Volume: 841,309 shs
• Average Volume: 590,230 shs
• Market Capitalization: C$1.22 billion
• P/E Ratio: N/A
• Dividend Yield: 7.26%
• Price Target: C$5.50
• Consensus Rating: Buy

NWH.UN Stock Analysis - Frequently Asked Questions

How have NWH.UN shares performed this year?

NorthWest Health Prop Real Est Inv Trust's stock was trading at C$4.45 at the beginning of the year. Since then, NWH.UN stock has increased by 11.5% and is now trading at C$4.96.

How do I buy shares of NorthWest Health Prop Real Est Inv Trust?

Shares of NWH.UN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Real Estate
• Industry: REIT - Healthcare Facilities
• Sub-Industry: N/A
• Current Symbol: TSE:NWH.UN
• CIK: N/A
• Web: www.nwhp.ca
• Phone: +1-416-3662000
• Fax: N/A
• Employees: 213
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NorthWest Health Prop Real Est Inv Trust: C$5.50
• High Price Target: C$5.75
• Low Price Target: C$5.25
• Potential Upside/Downside: +10.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): C($1.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 10.11
• P/E Growth: 0.74
• Net Income: -C$394.40 million
• Net Margins: -75.29%
• Pretax Margin: N/A
• Return on Equity: -14.67%
• Return on Assets: 2.91%

Debt

• Debt-to-Equity Ratio: 129.42
• Current Ratio: 0.25
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: C$523.85 million
• Price / Sales: 2.33
• Cash Flow: C$0.23 per share
• Price / Cash Flow: 21.67
• Book Value: C$7.14 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 246,300,000
• Free Float: N/A
• Market Cap: C$1.22 billion
• Optionable: Not Optionable
• Beta: 1.05